Zydus Cadila has received final approval from the US Food and Drug Administration to market Carboplatin injection.

“Zydus Cadila has received final approval from the US Food and Drug Administration to market Carboplatin injection,” the healthcare company says in its filing.

The group had received five approvals in last quarter ending March 2016. The group now has more than 100 approvals and has so far filed over 280 ANDAs, since commencement of filing process in FY04.

Press Announcement